Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jane Cunningham is active.

Publication


Featured researches published by Jane Cunningham.


Lancet Infectious Diseases | 2006

Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review

Karen R Steingart; Megan Henry; Vivienne Ng; Philip C. Hopewell; Andrew Ramsay; Jane Cunningham; Richard Urbanczik; Mark D. Perkins; Mohamed Abdel Aziz; Madhukar Pai

Most of the worlds tuberculosis cases occur in low-income and middle-income countries, where sputum microscopy with a conventional light microscope is the primary method for diagnosing pulmonary tuberculosis. A major shortcoming of conventional microscopy is its relatively low sensitivity compared with culture, especially in patients co-infected with HIV. In high-income countries, fluorescence microscopy rather than conventional microscopy is the standard diagnostic method. Fluorescence microscopy is credited with increased sensitivity and lower work effort, but there is concern that specificity may be lower. We did a systematic review to summarise the accuracy of fluorescence microscopy compared with conventional microscopy. By searching many databases and contacting experts, we identified 45 relevant studies. Sensitivity, specificity, and incremental yield were the outcomes of interest. The results suggest that, overall, fluorescence microscopy is more sensitive than conventional microscopy, and has similar specificity. There is insufficient evidence to determine the value of fluorescence microscopy in HIV-infected individuals. The results of this review provide a point of reference, quantifying the potential benefit of fluorescence microscopy, with which the increased cost and technical complexity of the method can be compared to determine the possible value of the method under programme conditions.


Lancet Infectious Diseases | 2006

Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review

Karen R Steingart; Vivienne Ng; Megan Henry; Philip C. Hopewell; Andrew Ramsay; Jane Cunningham; Richard Urbanczik; Mark D. Perkins; Mohamed Abdel Aziz; Madhukar Pai

In low-income and middle-income countries, direct (unconcentrated) sputum smear microscopy is the primary method for diagnosing pulmonary tuberculosis. The method is fast, inexpensive, and specific for Mycobacterium tuberculosis in high incidence areas. The main limitations of direct microscopy are its relatively low sensitivity, especially in individuals co-infected with HIV, and variable quality of the test in programme conditions. Thus, there is a need to identify methods to improve the sensitivity of microscopy. Physical and chemical sputum processing methods, including centrifugation, sedimentation, and bleach, have been studied and found to show promise. We did a systematic review to assess the ability of different processing methods to improve the sensitivity of microscopy. By searching many sources, we identified 83 studies. Overall, by comparison with direct smears, the results suggested that centrifugation with any of several chemical methods (including bleach) is more sensitive, that overnight sedimentation preceded by chemical processing is more sensitive, and that specificity is similar. There were insufficient data to determine the value of sputum processing methods in patients with HIV infection. Operational studies are needed to determine whether the increased sensitivity provided by processing methods is sufficient to offset their increased cost, complexity, and potential biohazards, and to examine their feasibility.


Nature | 2006

Reducing the Global Burden of Tuberculosis: The Contribution of Improved Diagnostics

Emmett B. Keeler; Mark D. Perkins; Peter M. Small; Christy Hanson; Steven G. Reed; Jane Cunningham; Julia E. Aledort; Lee Hillborne; Maria E. Rafael; Federico Girosi; Christopher Dye

We estimated the impact of hypothetical new diagnostic tests for tuberculosis (TB) in patients with persistent cough in developing countries. We found that a variety of new tests could help better identify TB cases and target treatment, thereby reducing the burden of disease.


Lancet Infectious Diseases | 2007

T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward.

Madhukar Pai; Keertan Dheda; Jane Cunningham; Fabio Scano; Richard O'Brien

For nearly a century, the tuberculin skin test was the only tool available for the detection of latent tuberculosis infection. A recent breakthrough has been the development of T-cell-based interferon-gamma release assays. Current evidence suggests interferon-gamma release assays have higher specificity than the tuberculin skin test, better correlation with surrogate markers of exposure to Mycobacterium tuberculosis in low-incidence settings, and less cross-reactivity as a result of BCG vaccination compared with the tuberculin skin test. The body of literature supporting the use of interferon-gamma release assays has rapidly expanded. However, several unresolved and unexplained issues remain. To address these issues, a group of experts met in Geneva, Switzerland, in March, 2006, to discuss the research evidence on T-cell-based assays, their clinical usefulness, limitations, and directions for future research, with a specific focus on resource-limited and high HIV prevalence settings. On the basis of 2 days of discussions, a comprehensive research agenda was generated, which will propel the field forward by stimulating focused high-impact research and encourage the investment of resources needed to tackle priority research questions, especially in resource-limited settings. Ultimately, if adequately financed, the research findings will inform appropriate use of novel latent tuberculosis infection diagnostics in global tuberculosis control.


Thorax | 2007

A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis

Karen R Steingart; Megan Henry; Suman Laal; Philip C. Hopewell; Andrew Ramsay; Dick Menzies; Jane Cunningham; Karin Weldingh; Madhukar Pai

Conventional diagnostic tests for tuberculosis have several limitations and are often unhelpful in establishing the diagnosis of extrapulmonary tuberculosis. Although commercial serological antibody based tests are available, their usefulness in the diagnosis of extrapulmonary tuberculosis is unknown. A systematic review was conducted to assess the accuracy of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. In a comprehensive search, 21 studies that reported data on sensitivity and specificity for extrapulmonary tuberculosis were identified. These studies evaluated seven different commercial tests, with Anda-TB IgG accounting for 48% of the studies. The results showed that (1) all commercial tests provided highly variable estimates of sensitivity (range 0.00–1.00) and specificity (range 0.59–1.00) for all extrapulmonary sites combined; (2) the Anda-TB IgG kit showed highly variable sensitivity (range 0.26–1.00) and specificity (range 0.59–1.00) for all extrapulmonary sites combined; (3) for all tests combined, sensitivity estimates for both lymph node tuberculosis (range 0.23–1.00) and pleural tuberculosis (range 0.26–0.59) were poor and inconsistent; and (4) there were no data to determine the accuracy of the tests in children or in patients with HIV infection, the two groups for which the test would be most useful. At present, commercial antibody detection tests for extrapulmonary tuberculosis have no role in clinical care or case detection.


Clinical Infectious Diseases | 2012

A Global Comparative Evaluation of Commercial Immunochromatographic Rapid Diagnostic Tests for Visceral Leishmaniasis

Jane Cunningham; Epco Hasker; Pradeep Das; Sayda El Safi; Hiro Goto; Dinesh Mondal; Margaret Mbuchi; Maowia M. Mukhtar; Ana Rabello; Suman Rijal; Shyam Sundar; Monique Wasunna; Emily R. Adams; Joris Menten; Rosanna W. Peeling; Marleen Boelaert

Accuracy of rapid diagnostic tests was high in the Indian subcontinent; however, in Brazilian and East African samples, reduced sensitivity suggests that several cannot be used alone to exclude visceral leishmaniasis. Data on ease of use and performance using whole blood and in human immunodeficiency virus coinfections is needed.


PLOS Neglected Tropical Diseases | 2015

Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors.

Qin Cheng; Jane Cunningham; Michelle L. Gatton

Background Sub-microscopic (SM) Plasmodium infections represent transmission reservoirs that could jeopardise malaria elimination goals. A better understanding of the epidemiology of these infections and factors contributing to their occurrence will inform effective elimination strategies. While the epidemiology of SM P. falciparum infections has been documented, that of SM P. vivax infections has not been summarised. The objective of this study is to address this deficiency. Methodology/Principal Findings A systematic search of PubMed was conducted, and results of both light microscopy (LM) and polymerase chain reaction (PCR)-based diagnostic tests for P. vivax from 44 cross-sectional surveys or screening studies of clinical malaria suspects were analysed. Analysis revealed that SM P. vivax is prevalent across different geographic areas with varying transmission intensities. On average, the prevalence of SM P. vivax in cross-sectional surveys was 10.9%, constituting 67.0% of all P. vivax infections detected by PCR. The relative proportion of SM P. vivax is significantly higher than that of the sympatric P. falciparum in these settings. A positive relationship exists between PCR and LM P. vivax prevalence, while there is a negative relationship between the proportion of SM P. vivax and the LM prevalence for P. vivax. Amongst clinical malaria suspects, however, SM P. vivax was not identified. Conclusions/Significance SM P. vivax is prevalent across different geographic areas, particularly areas with relatively low transmission intensity. Diagnostic tools with sensitivity greater than that of LM are required for detecting these infection reservoirs. In contrast, SM P. vivax is not prevalent in clinical malaria suspects, supporting the recommended use of quality LM and rapid diagnostic tests in clinical case management. These findings enable malaria control and elimination programs to estimate the prevalence and proportion of SM P. vivax infections in their settings, and develop appropriate elimination strategies to tackle SM P. vivax to interrupt transmission.


Malaria Journal | 2014

Plasmodium falciparum parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting

Qin Cheng; Michelle L. Gatton; John W. Barnwell; Peter L. Chiodini; James S. McCarthy; David Bell; Jane Cunningham

Malaria rapid diagnostic tests (RDTs) play a critical role in malaria case management, surveillance and case investigations. Test performance is largely determined by design and quality characteristics, such as detection sensitivity, specificity, and thermal stability. However, parasite characteristics such as variable or absent expression of antigens targeted by RDTs can also affect RDT performance. Plasmodium falciparum parasites lacking the PfHRP2 protein, the most common target antigen for detection of P. falciparum, have been reported in some regions. Therefore, accurately mapping the presence and prevalence of P. falciparum parasites lacking pfhrp2 would be an important step so that RDTs targeting alternative antigens, or microscopy, can be preferentially selected for use in such regions. Herein the available evidence and molecular basis for identifying malaria parasites lacking PfHRP2 is reviewed, and a set of recommended procedures to apply for future investigations for parasites lacking PfHRP2, is proposed.


Clinical Infectious Diseases | 2008

Cost-Effectiveness Analysis of Introduction of Rapid, Alternative Methods to Identify Multidrug-Resistant Tuberculosis in Middle-Income Countries

Carlos Acuna-Villaorduna; Anna Vassall; German Henostroza; Carlos Seas; Humberto Guerra; Lucy Vasquez; Nora Morcillo; Juan Saravia; Richard O'Brien; Mark D. Perkins; Jane Cunningham; Luis F. Llanos-Zavalaga; Eduardo Gotuzzo

BACKGROUND Resistance to commonly used antituberculosis drugs is emerging worldwide. Conventional drug-susceptibility testing (DST) methods are slow and demanding. Alternative, rapid DST methods would permit the early detection of drug resistance and, in turn, arrest tuberculosis transmission. METHODS A cost-effectiveness analysis of 5 DST methods was performed in the context of a clinical trial that compared rapid with conventional DST methods. The methods under investigation were direct phage-replication assay (FASTPlaque-Response; Biotech), direct amplification and reverse hybridization of the rpoB gene (INNO-LiPA; Innogenetics), indirect colorimetric minimum inhibitory concentration assay (MTT; ICN Biomedicals), and direct proportion method on Löwenstein-Jensen medium. These were compared with the widely used indirect proportion method on Löwenstein-Jensen medium. RESULTS All alternative DST methods were found to be cost-effective, compared with other health care interventions. DST methods also generate substantial cost savings in settings of high prevalence of multidrug-resistant tuberculosis. Excluding the effects of transmission, the direct proportion method on Löwenstein-Jensen medium was the most cost-effective alternative DST method for patient groups with prevalences of multidrug-resistant tuberculosis of 2%, 5%, 20%, and 50% (cost in US


PLOS Neglected Tropical Diseases | 2015

The Case for Improved Diagnostic Tools to Control Ebola Virus Disease in West Africa and How to Get There.

Arlene C. Chua; Jane Cunningham; Francis Moussy; Mark D. Perkins; Pierre Formenty

2004,

Collaboration


Dive into the Jane Cunningham's collaboration.

Top Co-Authors

Avatar

Michelle L. Gatton

Queensland University of Technology

View shared research outputs
Top Co-Authors

Avatar

Qin Cheng

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

David Bell

World Health Organization

View shared research outputs
Top Co-Authors

Avatar

Mark D. Perkins

Foundation for Innovative New Diagnostics

View shared research outputs
Top Co-Authors

Avatar

Iveth J. González

Foundation for Innovative New Diagnostics

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sandra Incardona

Foundation for Innovative New Diagnostics

View shared research outputs
Top Co-Authors

Avatar

John W. Barnwell

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Andrew Ramsay

World Health Organization

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge